慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨*

doi:10.3969/j.issn.1672-5069.2019.06.023

摘要/Abstract

摘要： 目的探讨外周血Treg和Th17细胞比率检测在评估HCV感染患者发生肝硬化的临床意义。方法 2017年3月~2019年1月我院收治的丙型肝炎肝硬化患者35例、慢性丙型肝炎（CHC）患者31例和同期接受健康体检者66名,采用ELISA法检测血清白细胞介素-6（IL-6）、IL-17和转化生长因子-β（TGF-β）水平,使用流式细胞仪检测外周血Treg和Th17细胞比率。绘制ROC曲线观察各指标预测肝硬化的发生。结果丙型肝炎肝硬化患者血清IL-6、IL-17和TGF-β水平分别为（8.08±2.71） ng/L、（17.01±4.55） ng/L和（5.20±1.35） ng/L,显著高于健康人[分别为（6.64±2.33） ng/L、（12.76±3.46） ng/L和（4.19±1.07） ng/L,P<0.05]或CHC 患者[分别为（7.20±2.49） ng/L、（14.12±3.87） ng/L和（4.41±1.20） ng/L,P<0.05],血清高水平的TGF-β能预测肝硬化的发生（AUC=0.963,P=0.000）;肝硬化患者外周血Treg细胞比率为（6.27±1.02）%,显著高于CHC患者或健康人[分别为（5.75±0.84） %和（5.37±0.99） %,P<0.05],而Th17/Treg比值为（0.19±0.05）,显著低于CHC患者或健康人[分别为（0.23±0.06）和（0.22±0.05）,P<0.05];ROC曲线分析显示外周血Treg细胞比率或Th17/Treg细胞比值可有效预测肝硬化[AUC=0.820和AUC=0.607,P=0.000,P=0.041],而TH17细胞对肝硬化无预测价值。结论丙型肝炎肝硬化患者血清TGF-β水平和外周血Treg细胞比率有明显的变化,监测它们的变化可能有助于在慢性丙型肝炎病毒感染者中早期发现肝硬化,做到早诊断、早治疗,对改善预后有重要的临床意义。

关键词: 丙型肝炎, 肝硬化, Treg细胞, 细胞因子, 预测

Abstract: Objective The aim of this study was to investigate the clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C（CHC） and hepatitis C-induced liver cirrhosis （LC）. Methods 35 patients with CHC-induce LC,31 patients with CHC and 66 healthy subjects were enrolled in our hospital between March 2017 and January 2019. Serum interleukin-6（IL-6）,IL-17 and transforming growth factor-β （TGF-β） were assayed by ELISA,and peripheral blood Treg and Th17 cells were detected by FCM. The area under ROC curve（AUC） was drawn to observe the predictive value of liver cirrhosis by each parameters. Results Serum IL-6,IL-17 and TGF-β levels in patients with LC were （8.08±2.71）ng/L,（17.01±4.55）ng/L and （5.20±1.35） ng/L,significantly higher than [（6.64±2.33） ng/L,（12.76±3.46） ng/L and （4.19±1.07） ng/L,respectively,P<0.05] in healthy individuals or [（7.20±2.49） ng/L,（14.12±3.87） ng/L and （4.41±1.20） ng/L,respectively,P<0.05] in patients with CHC,and high serum TGF-βlevel could predict LC （AUC=0.963,P=0.000）;peripheral blood Treg cell percentage in patients with LC was（6.27±1.02） %,significantly higher than （5.75±0.84） % and （5.37±0.99） %,respectively （P<0.05） in patients with CHC or in healthy persons,while the ratio of Th17/Treg cells was （0.19±0.05）,much lower than （0.23±0.06） and （0.22±0.05）,respectively,in patients with CHC or in healthy persons （P<0.05）;ROC analysis showed that peripheral blood Treg cell percentage （AUC=0.820,P=0.000） or the ratio of Th17/Treg cells （AUC=0.607,P=0.041） could,while the TH17 cell percentage couldn’t predict the existence of LC. Conclusion Serum TGF-β level and peripheral blood Treg cells in patients with hepatitis C-induced LC changes obviously, which might make difference from in patients with chronic hepaitits C and help predict liver disease stage and diagnose LC early.

Key words: Liver cirrhosis, Hepatitis C, Treg cells, Cytokines, Prediction

杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.

Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.

参考文献

[1] 梅昭荷,聂红明,汪蓉,等. 从Th1/Th2、Treg/Th17之间的平衡研究轻、中度慢性乙型肝炎患者CD4+T淋巴细胞的免疫失衡状态.肝脏,2017,22(6):513-516.
[2] Kondo Y,Ninomiya M,Kimura O,et al.HCV infection enhances Th17 commitment,which could affect the pathogenesis of autoimmune diseases. PLoS One,2014,9(6):98521-98524.
[3] 马海霞,李嘉,刘勇钢,等. 肝内调节性T淋巴细胞与辅助性T淋巴细胞17平衡在不同阶段慢性乙型肝炎病毒感染者中的作用. 中华传染病杂志,2018,36(3):133-134.
[4] 中华医学会肝病学分会和感染病学分会. 《丙型肝炎防治指南》2015年更新版. 实用肝脏病杂志,2016,19(4):ⅠⅩ-ⅩⅩⅤⅠ.
[5] 吴丽蒙. Treg和Th17细胞在慢加急性乙型肝炎肝衰竭发病机制中的作用研究进展. 实用肝脏病杂志,2017,20(5):639-642.
[6] Harfouch S,Guiguet M,Valantin MA,et al.Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection.J Hepatol,2012,56(6):1259-1268.
[7] Odigie M,Osinusi A,Barrett L,et al.Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients. AIDS Res Hum Retrovir,2014,30(8):775-782.
[8] Sun LJ,Yu JW,Shi YG,et al.Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1. J Med Virol,2018,90(5):926-935.
[9] Shachar I,Karin N.The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol,2013,93(1):51-61.
[10] Nafady A,Nafady-Hego H, Abdelwahab NM,et al.Peripheral lymphocytes analyses in children with chronic hepatitis C virus infection. Eur J Clin Invest,2018,48(10):13004-13007.
[11] Szereday L,Meggyes M,Halasz M,et al.Immunological changes in different patient populations with chronic hepatitis C virus infection. World J Gastroenterol,2016,22(20):4848-4859.
[12] Nakatsuka K,Atsukawa M,Shimizu M,et al.Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol,2015,7(25):2590-2596.
[13] Maggio R,Viscomi C,Andreozzi P,et al.Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection. PLoS One,2014,9(12):112346-112349.
[14] Baharlou R,Romani B,Kiani SJ,et al.Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol,2018,207(1):65-74.
[15] Baharlou R,Romani B,Kiani SJ,et al.Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol,2018,207(1):65-74.
[16] Nady S,Esmat G.IL-17 induced the recruitment and functional activity of granulocytes isolated from patients coinfected with Schistosoma mansoni and hepatitis C virus. Egypt J Immunol,2017,24(1):9-20.
[17] Hetta HF,Elkady A,Morsy KH,et al.Serum level of IL17a among cirrhotic hepatitis C virus infected patients with incidence of diabetes mellitus. Egypt J Immunol,2017,24(1):79-88.
[18] Lee HC,Sung SS,Krueger PD,et al.Hepatitis C virus promotes T-helper (Th) 17 responses through thymic stromal lymphopoietin production by infected hepatocytes. Hepatology,2013,57(4):1314-1324.
[19] Nady S,Ezz A,El-Shorbagy A,et al.HCV infection amplified Th2 bias and Th17 responses in Schistosoma-infected patients. Egypt J Immunol,2016,23(1):87-96.
[20] Kotsiri I,Hadziyannis E,Georgiou A,et al.Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy. Ann Gastroenterol,2018,29(1):79-84.
[21] Abd El-Meguid M,Dawood RM,Mokhles MA,et al. Extrahepatic upregulation of transforming growth factor beta 2 in HCV genotype 4-induced liver fibrosis. J Interferon Cytokine Res,2018,38(8):341-347.
[22] Subramanian V,Bharat A,Vachharajani N,et al.Perioperative blood transfusion affects hepatitis C virus(HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients. HPB (Oxford),2014,16(3):282-294.

慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*

Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[4]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[5]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[6]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[9]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[12]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[13]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[14]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[15]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.